SCHEMBL31225239

SCHEMBL31225239

O=C(O)Cc1ccc(-c2ccccc2)c(O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.63
TSHR P16473 3/20 0.63
LMNA P02545 2/20 0.63
KDM4E B2RXH2 2/20 0.63
NFKB1 P19838 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
RGS12 O14924 1/20 0.63
POLB P06746 1/20 0.63
MAPT P10636 1/20 0.63
HPGD P15428 1/20 0.63
APEX1 P27695 1/20 0.63
THPO P40225 1/20 0.63
BLM P54132 1/20 0.63
GNAI1 P63096 1/20 0.63
PMP22 Q01453 1/20 0.63
HIF1A Q16665 1/20 0.63
HSD17B10 Q99714 1/20 0.63
ABCC4 O15439 1/20 0.60
PTGS1 P23219 1/20 0.60
HTT P42858 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11288680 0.87 GAA (0.61) GAATSHRLMNAKDM4ENFKB1
SCHEMBL3839814 0.87 PSEN1 (0.66) GAATSHRLMNAKDM4ENFKB1
SCHEMBL28174998 0.86 HPGD (0.51) GAATSHRLMNAKDM4ENFKB1
SCHEMBL17187836 0.84 LMNA (0.69) GAATSHRLMNAKDM4ENFKB1
SCHEMBL11849675 0.82 LMNA (0.56) GAATSHRLMNAKDM4ENFKB1
SCHEMBL11845598 0.82 LMNA (0.56) GAATSHRLMNAKDM4ENFKB1
SCHEMBL10713778 0.82 LMNA (0.56) GAATSHRLMNAKDM4ENFKB1
Felbinac SCHEMBL5483050 0.82 ABCC4 (0.72) GAATSHRLMNAHPGDHSD17B10
SCHEMBL11839181 0.82 CSNK2A1 (0.62) GAATSHRLMNAKDM4ENFKB1
SCHEMBL5822623 0.82 DGAT1 (0.56) GAATSHRLMNAKDM4ENFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF SIGLEC7, SIGLEC9, CD2BP2 GAA 525/4885TSHR 1160/4885LMNA 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.